Top Health Tech Companies in Dublin (81)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.
Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.
Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.
Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.
Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.
The Avoca Clinic is Ireland’s leading Plastic Surgery Clinic for a reason. Located in multiple discrete locations around the country, you’ll immediately feel the warmth and luxury of our beautifully designed spaces that are home to some of the most technologically advanced equipment and world-class surgeons. Offering the very latest procedures and techniques available to the cosmetic surgery industry, we...
Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and developing meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. Our...
A public company, founded over 25 years ago, Consensus is the global leader in digital cloud and fax technology. Focusing in the healthcare space, we use interoperability to unify multiple systems that wouldn’t otherwise talk to each other. With exciting new initiatives on the horizon, we are continuing our strategic expansion. Read on to learn why now is the ideal...
Consensus Cloud Solutions's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst recognition placed the company among the Leaders in worldwide digital fax, supporting a top-tier position in its core niche. Long tenure and scale around the eFax franchise plus regulated-workflow add-ons reinforce defensibility in compliance-heavy document exchange.
Healthy Cash Flow: Free cash flow increased to a record level in 2025, indicating strong cash generation even amid mixed topline performance. Operating cash flow also rose, providing flexibility to fund strategy and capital allocation.
Profitability: Adjusted EBITDA remained very high with margins around the low-50% range, signaling durable profitability. Guidance also points to continued strong earnings power alongside modest revenue growth expectations.
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion...
We are a biotech longevity company on a mission to confront aging and age-related diseases. We’re building a coalition of the best scientists, physicians and investors to develop therapies and products that will help people experience better health for longer in their lives. We are organized to drive scientific innovation with speed and agility to market
Fettle is a digital behavioral healthcare company. We provide clients easy access to a diverse range of qualified and insured mental health professionals. Fettle was founded with the ideal that mental health is a universal need and that everyone struggles sometimes. Using technology and data science coupled with a human touch; Fettle enables seamless virtual delivery of mental health support....
At Fitbit, we created an entire industry around wearable technology with software and services to help people transform their lives for the better, from the smallest milestones to the biggest changes. 10k steps started out as a magic number and became an anthem for setting goals—but today, we take the Fitbit community well beyond it. Our global teams are on...
ABC Glofox is on a mission to build a healthier world. We are a venture-backed product-led SaaS company that is in hyper-growth. Along with our ever-growing client base that spans over 60 countries, our team is dedicated to powering the fitness industry with digital solutions. We are one team consisting of honest, moral, and ethical individuals who are heard and...
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. We are navigating the complexities of healthcare and providing scaled...
Cardinal Health's Top Stability & Growth Strengths
Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.
Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.
Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.
Uniphar is a diversified healthcare services organisation with activities in Ireland, UK, Europe, the USA and APAC
Affidea is a pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider, operating in Greece since 2005 to offer high-quality, integrated primary health services.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
The Wellola team believes only the sickest of the sick should be hospitalised and that the future of healthcare is preventative, community-based and supported by digital tools. Wellola prides itself in being highly user-focused, reliable, robust and easy-to-use. Our team have unique, in-depth sector know-how, our pricing model is extremely cost effective and our business model is scalable for national...
4G Clinical is driven by a single purpose: bring crucial medicines to those who need them, faster. 4G Clinical believes that the way to accelerate clinical research is by disrupting the way trials are executed. That’s why we have revolutionized RTSM (randomization and trial supply management) and supply forecasting capabilities and services from the ground up.
X-Bolt brings simplicity and efficiency to trauma surgery, whilst improving quality of life for patients
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of...
Bristol Myers Squibb's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests BMS holds a top‑tier global position with anchor franchises like Eliquis and Opdivo and a broad oncology footprint including cell therapies, reinforcing sustained competitive advantage.
Product Line Growth: Feedback suggests the company’s “growth portfolio” of newer medicines is expanding strongly, with assets such as Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy helping to offset legacy declines.
Future-Ready Strategy: Feedback suggests recent acquisitions and collaborations (Karuna/Cobenfy, RayzeBio, Mirati, BioNTech) broaden modalities and late‑decade growth drivers, positioning the company to sustain leadership beyond current headwinds.
We save lives by ensuring that patients get the best test first. xRefer, our smart radiology referral platform, is now live
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power.
Bayer's Top Stability & Growth Strengths
Strong Market Position & Advantage: Bayer is positioned as a clear front-runner in Crop Science, with particularly strong standing when seeds/traits and digital agriculture are included alongside crop protection. It is also consistently placed within the top cohort globally in OTC/self-care, supporting leadership credibility across major end-markets.
Innovation-Driven Growth: Innovation activity is emphasized across seeds/traits, biologics, and digital farming, with multiple launches and late-stage programs cited as reinforcing Bayer’s pace-setting role in ag inputs. Newer pharmaceutical products like Nubeqa and Kerendia are described as ramping and helping offset headwinds from older brands.
Diversified Revenue Streams: The company operates across Crop Science, Pharmaceuticals, and Consumer Health, providing multiple earnings levers even when one segment faces cycle or lifecycle pressure. Incremental growth is highlighted as coming from Crop Science seeds/traits and newer Pharma assets while other categories remain flatter.
